Pfizer Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Monday 21st, July 2025
External Deadline: Thursday 24th, July 2025
Description
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: June 5, 2025
Geographic Scope: Global
Clinical Area: Oncology – Hematology – Multiple Myeloma
Link to full RFP: Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Application Due Date: July 24, 2025
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- – Safety and efficacy of elranatamab in the context of real-world use
- – Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies
- – Impact of prior treatments (BsAb, CAR-T, ADC) on elranatamab outcomes, and wash-out period between treatments
- – Infection patterns, timing, types, and management strategies including Ig replacement therapy
– Identifying clinical and biological features of refractoriness, early- or late-response, relapse to elranatamab and establishing response biomarkers
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).